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A B S T R A C T
A novel innate immune strategy, involving specific cholesterol oxidation products as effectors, has begun to reveal connections between cholesterol metabolism and
immune response against viral infections. Indeed, 25-hydroxycholesterol (25HC) and 27-hydroxycholesterol (27HC), physiologically produced by enzymatic oxi-
dation of cholesterol, act as inhibitors of a wide spectrum of enveloped and non-enveloped human viruses. However, the mechanisms underlying their protective
effects against non-enveloped viruses are almost completely unexplored. To get insight into this field, we investigated the antiviral activity of 25HC and 27HC against
a non-enveloped virus causing acute gastroenteritis in children, the human rotavirus (HRV). We found that 25HC and 27HC block the infectivity of several HRV
strains at 50% inhibitory concentrations in the low micromolar range in the absence of cell toxicity. Both molecules affect the final step of virus penetration into cells
by preventing the association of two cellular proteins: the oxysterol binding protein (OSBP) and the vesicle-associated membrane protein-associated protein-A (VAP-
A). By altering the activity of these cellular mediators, 25HC and 27HC disturb the recycling of cholesterol between the endoplasmic reticulum and the late
endosomes which are exploited by HRV to penetrate into the cell. The substantial accumulation of cholesterol in the late endosomal compartment results in
sequestering viral particles inside these vesicles thereby preventing cytoplasmic virus replication. These findings suggest that cholesterol oxidation products of
enzymatic origin might be primary effectors of host restriction strategies to counteract HRV infection and point to redox active lipids involvement in viral infections
as a research area of focus to better focus in order to identify novel antiviral agents targets.
Introduction
Innate immune response is the first line of defense during the ear-
liest hours of exposure to a novel pathogen. Its mechanisms are non-
specific and rely on a group of proteins and phagocytic cells that
quickly activate to help destroy invaders. Alongside these pathways, a
novel innate immune strategy has begun to reveal connections between
cholesterol metabolism and immune response against viral infections.
[1–3].
The most widely studied effector of this branch of innate immunity
is an oxysterol, 25-hydroxycholesterol (25HC) [1,2]. Oxysterols contain
27 carbon atoms per molecule and are derived from cholesterol by both
enzymatic and nonenzymatic oxidation [4–6]. Several among the var-
ious cholesterol oxidation products of enzymatic origin contribute to
physiological functions: they are intermediates of pregnenolone and
steroid hormone synthesis [7] and target nuclear receptors (e.g., the
liver X receptor [LXR] and the estrogen receptor α [ER α]), cellular
membrane receptors (e.g., C-X-C motif chemokine receptor 2 [CXCR2])
and transport proteins (e.g., insulin induced gene protein [INSIG],
Niemann-Pick protein 1 [NPC1], oxysterol binding protein [OSBP] and
its related proteins [ORPs]) [8–13]. In contrast, the oxysterols derived
from cholesterol autoxidation, a not-regulated and therefore potentially
harmful biochemical reaction, appear to be more likely involved in
pathophysiological processes associated with inflammation and oxida-
tive stress [4,5,14].
In 2013 Blanc and colleagues provided in vitro findings indicating
that 25HC acts as a physiological interferon (IFN)-induced effector of
innate immunity against viral infections [1]. They reported that 25HC
was the only oxysterol synthesized and secreted by macrophages upon
IFN treatment or virus infection and that transcription factor Stat1 di-
rectly couples IFN-stimulated signaling to regulation of the cholesterol
hydroxylase gene (Ch25h) encoding the 25HC-synthesizing enzyme.
Unlike known antiviral small molecules that target highly specific
viral determinants, thus showing a restricted spectrum of activity,
25HC inhibits the replication of a wide spectrum of pathogenic viruses.
This includes both enveloped viruses, i.e., those with a phospholipidic
bilayer outside the proteic capsid such as human immunodeficiency
virus (HIV), herpes simplex virus type 1 (HSV-1), varicella zoster virus
(VZV) murine cytomegalovirus (MCMV), vesicular stomatitis virus
(VSV), Ebola virus (EBOV), Zika virus, hepatitis C virus, and
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orthomixovirus [1,2,15–19], and non-enveloped viruses such as human
rhinovirus (HRhV) [20–22], human papillomavirus (HPV), and human
rotavirus (HRV) [21].
This unprecedented range of antiviral properties is ascribable to the
ability of 25HC to modulate cellular lipid metabolism and transport,
thereby modifying the composition and structure of cellular and sub-
cellular membranes [23,24]. Since viral pathogens have to pass through
cellular lipid membranes or hijack them to assemble their replicative
machinery, regulation of the lipid composition of cellular and sub-
cellular membranes looks like a particularly smart and effective
strategy to counteract viral invasion from a strictly evolutionary point
of view.
The mechanisms underlying the antiviral activity of 25HC have
been extensively investigated for a number of enveloped viruses: 25HC
might alter the lipid composition of cellular membranes, thus ham-
pering the fusion between the viral envelope and the cytoplasmic lipid
bilayer that allows some enveloped viruses to penetrate into the host
cell [1]. This oxysterol directly changes cell membrane properties by
inserting itself into the lipid bilayer [2]. Moreover, various studies on
25HC-induced host response to HCV infection clearly correlated this
protective action with an imbalance in the mevalonate pathway by the
oxysterol [17,25–27], implying the inhibition of cholesterol synthesis
and depletion of non-sterol isoprenoid products, in this way impairing
cholesterol membrane content and protein prenylation [17,25–28]. Of
note, our group showed that 25HC but also a second enzymatically
synthesized oxysterol, 27-hydroxycholesterol (27HC) can stimulate the
release of interleukin 6 (IL6) and are endowed with an anti-HSV-1 ac-
tivity which is apparently non-unrelated to the viral entry inhibition
[19].
By contrast, the mechanisms underlying the protective effects of
cholesterol oxidation products against non-enveloped viruses are lar-
gely unexplored, with the unique exception of HRhV [22] and 25HC as
the only oxysterol examined so far [22]. In fact, this oxysterol has been
shown to markedly reduce the accumulation of phosphatidylinositol 4-
phosphate (PI4P) in the Golgi apparatus, a crucial event for the as-
sembly of HRhV replicative machinery, by targeting members of the
OSBP family I [20,22].
With regard to non-enveloped viruses, we previously described the
antiviral activity exerted by 25HC and 27HC, particularly against HRV
[21]. We investigated the mechanism of action of 25HC and 27HC
against HRV to shed a light on an almost totally unexplored scenario,
which may hold promise to reveal novel antiviral mechanisms and
targets, likely exploitable for a new generation of antiviral molecules.
HRV belongs to the reoviridae family and represents one of the
leading causes of infective gastroenteritis in children [29]. Its genome
consists of 11 segments of double-stranded RNA encoding six structural
proteins (VP1–VP4,VP6, and VP7) and six non-structural proteins
(NSP1–NSP6). The mature virion is a triple-layered particle (TLP) about
100 nm in diameter and consists of an inner layer (the core) composed
of the viral proteins VP1 and VP2, an intermediate layer (the inner
capsid made of VP6), and an outer layer (the outer capsid consisting of
VP7 and projections of VP4) [30,31], with VP4 being the major de-
terminant of tropism and receptor binding [32–35].
HRVs exploit the endocytic route to enter cells. Various human
strains, such as HRV Wa, WI61, and DS-1, travel along this intracellular
path to reach the late endosomes (LEs) [36]. Once inside the LEs, a
sequence of molecular transformations in the outer-layer proteins VP7
and VP4 strips the proteins from the virion (i.e., the TLP) and delivers
into the cytosol an inner capsid particle, known as the double-layered
particle or DLP [37].
Here we report on an original mechanism of antiviral action by
oxysterols against HRV. We found that both 25HC and 27HC block HRV
cell entry and replication by inducing an accumulation of cholesterol in
the LEs, thereby sequestering viral particles inside these vesicles. These
findings represent a step forward in our understanding the role oxy-
sterols play as effectors of innate immunity against viral infections.
Results
Anti-HRV effect of 25HC and 27HC and their spectrum of activity
In a previous study, we reported on the inhibitory activity of 25HC
and 27HC against the Wa strain of HRV [21]. To explore the spectrum
of anti-HRV activity, 25HC and 27HC were tested against four addi-
tional HRV strains (WI61, HRV 408, HRV 248, DS-1) in MA104 cells. As
shown in Table 1, the antiviral activity of both 25HC and 27HC is not
strain-restricted, with EC50 values falling in the low micromolar range
and favorable selectivity index (SI) for all the HRV strains tested. Both
oxysterols inhibited HRV infection in a dose-dependent fashion (Fig. 1).
The antiviral potency of 25HC was significantly (pFtest < 0.001) higher
than that of 27HC against each strain tested. Since most of the assays of
the mechanism of action described below were performed by testing
25HC and 27HC against high viruses/target cell ratios (MOI, multi-
plicity of action), we verified that both molecules were able to inhibit
HRV infectivity also under these conditions. Indeed, they significantly
inhibited HRV infectivity to a maximum of 90% even at high MOI (MOI
10) (Fig. 3). Finally, 25HC and 27HC were also tested against HRV
infection of human intestinal Caco2 cell line to determine whether their
antiviral activity was influenced by the cellular model. The two oxy-
sterols displayed a strong antiviral effect in both MA104 and Caco2
cells, two quite different cellular models (Tables 1 and 2; Figs. 1 and 2),
thus indicating that their activity is not cell line dependent.
Table 1
Antirotavirus activity of oxysterols (MA104 cells).
Oxysterols HRV strain EC50a (µM) – 95% CIb EC90c (µM) – 95% CI CC50d(µM) –95% CI SIe
25HC Wa 0.16 (0.12–0.20) 1.37 (0.75–2.40) > 150 > 938
WI61 0.09 (0.08–0.12) 0.28 (0.16–0.46) > 150 > 1667
HRV408 0.12 (0.09–0.16) 0.42 (0.23–0.74) > 150 > 1250
HRV248 0.11 (0.07–0.18) 1.26 (0.47–3.38) > 150 > 1364
DS-1 0.27 (0.14–0.53) 5.77 (1.15–28.89) > 150 > 556
27HC Wa 0.26 (0.22–0.31) 1.73 (1.21–2.47) > 150 > 577
WI61 0.19 (0.14–0.27) 0.74 (0.35–1.55) > 150 > 790
HRV408 0.40 (0.26–0.62) 4.56(1.62–12.82) > 150 > 375
HRV248 0.23 (0.12–0.46) 3.84 (0.80–18.39) > 150 > 652
DS-1 0.72 (0.49–1.06) 5.85 (2.43–14.06) > 150 > 208
n.a. not assessable.
a EC50 half-maximal effective concentration.
b CI confidence interval.
c EC9090% effective concentration.
d CC50 half maximal cytotoxic concentration
e SI selectivity index.
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25HC and 27HC inhibit HRV-cell penetration
Specific assays were performed to identify which step(s) of the HRV
replicative cycle was inhibited by the two oxysterols. Time-of-addition
assays showed that 25HC and 27HC exerted their highest antiviral
efficacy when added to cells 20 h before infection (Fig. 4A-B). By con-
trast, when the treatment was performed after viral infection, no anti-
viral effect was observed. These data suggest that both oxysterols
modify the cellular milieu so as to render the cells less susceptible to
HRV most likely by targeting cellular determinants essential for virus
Fig. 1. Antiviral activity of 25HC and 27HC against HRV strains Wa (A), DS-1 (B), HRV 408 (C), WI61 (D), and HRV 248 (E) on MA104 cells. Cells were treated for
20 h with increasing concentrations of oxysterols and then infected. Viral infections were detected as described in the Material and Methods section. The percentage
infection was calculated by comparing treated and untreated wells. The results are means and SEM for triplicates.
Table 2
Antirotavirus activity of oxysterols (Caco2 cells).
Oxysterols HRV strain EC50a (µM) – 95%
CIb





25HC Wa 0.19 (0.14–0.25) 1.26 (0.61–2.60) > 150 > 789
WI61 0.25(0.20–0.31) 0.83(0.50–1.38) > 150 > 600
HRV408 0.42(0.36–0.48) 2.30(1.66–3.18) > 150 > 357
HRV248 0.21(0.16–0.28) 1.04(0.55–1.94) > 150 > 714
DS-1 0.43 (0.29–0.63) 2.42 (1.04–5.63) > 150 > 349
27HC Wa 0.44 (0.34–0.56) 2.50 (1.45–4.29) > 150 > 341
WI61 0.34(0.22–0.53) 2.43(0.90–6.59) > 150 > 441
HRV408 0.81(0.60–1.09) 3.78(1.94–7.36) > 150 > 185
HRV248 0.41(0.35–0.48) 2.70(1.90–3.83) > 150 > 366
DS-1 0.45 (0.34–0.61) 2.62 (1.37–5.03) > 150 > 333
n.a. not assessable.
a EC50 half-maximal effective concentration.
b CI confidence interval.
c EC9090% effective concentration.
d CC50 half maximal cytotoxic concentration.
e SI selectivity index.
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penetration or replication. Of note, as displayed in Fig. 4C, the indirect
immunocytochemistry clearly shows that no deposition of neo-synthe-
tized HRV antigen occurs in both MA104 and Caco2 cells at 20 h post
infection, when infection was stopped by fixing cells. Taken together,
these results suggested that 25HC and 27HC were able to affect the
steps of the HRV replicative cycle occurring before HRV protein
synthesis. For this reason, we investigated the effect of oxysterols on the
earliest steps of HRV replication, i.e. virus binding and penetration.
Binding assay experiments clearly showed that treatment with both
25HC and 27HC had no effect on HRV attachment to the cell surface
(Fig. 5 panel A).
In a second set of experiments, we assessed the ability of the oxy-
sterols to alter HRV entry kinetics into the cells. Both 25HC and 27HC
significantly (0.001 <pANOVA<0.05) hampered normal virus-cell
penetration, when measured as a function of viral particles that enter
cells and carry out a single replication cycle (Fig. 5B). Consistent with
previous results (Fig. 1), 25HC affected HRV entry kinetics more po-
tently than 27HC.
HRV penetration into the host cell is a complex event involving re-
ceptor-mediated endocytosis, LE membrane permeabilization, and release
of the virus particle into the cytoplasm where viral replication occurs.
Interestingly, when we forced by means of Lipofectamine the infection of
an ethylene glycol tetraacetic acid (EGTA)-inactivated HRV suspension,
thereby bypassing viral entry through endocytosis, 25HC and 27HC
showed no antiviral activity (Fig. 5C). Consistently with these results,
when we added oxysterols on infected cells after NH4Cl treatment (i.e.
after the HRV exit from LEs) no antiviral activity was measurable
(Fig. 5D). More importantly, we analyzed the intracellular localization of
HRV 8 h post-inoculum, when most of the virus particles have already
escaped from the LEs and replicate in the cytoplasm where newly syn-
thesized viral proteins accumulate. As expected, confocal immune mi-
croscopy revealed that the viral antigen VP6 was mostly diffused in the
cytoplasm of untreated infected cells (Fig. 6). By contrast, in both the
25HC- and the 27HC-treated cells, almost all VP6 co-localized with a
marker of LEs (Rab-7). Taken together, these results indicate that 25HC
and 27HC affect HRV entry by sequestering the virus particles penetrating
the LEs and preventing their replication in the cytoplasm.
Fig. 2. Antiviral activity of 25HC and 27HC against HRV strains Wa (A), DS-1 (B), HRV 408 (C), WI61 (D), and HRV 248 (E) on Caco2 cells. The results are means and
SEM for triplicates.
Fig. 3. Antiviral activity of 25HC and 27HC against HRV Wa at multiplicity of
infection (MOI) 10, 3, and 1 on MA104 cells. Cells were treated for 20 h with
25HC or 27HC at EC90 concentrations and then infected. Viral infections were
detected as described in the Material and Methods section. The percentage
infection was calculated by comparing treated and untreated wells. The results
are means and SEM for triplicates. ***pANOVA< 0.001.
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OSBP and VAP-A are cellular determinants of 25HC and 27HC anti-HRV
activity
To elucidate the mechanism by which 25HC and 27HC block HRV
penetration in the LEs, we focused our attention on the cellular protein
OSBP, one of the main intracellular interactors of oxysterols. Proteins
that prevent OSBP association with the vesicle-associated membrane
protein-associated protein A (VAP-A) are known to disrupt intracellular
cholesterol homeostasis, leading to cholesterol accumulation on the LEs
membrane. This event has been shown to inhibit the entry of specific
enveloped viruses [38,39]. Although this mechanism has been postu-
lated only for enveloped viruses, we hypothesized that the model of a
“greasy response” to viral infection - as defined by Tanner and collea-
gues in 2013 [39] - could fit with our results (Fig. 6). In specific assays
to verify whether this mechanism applies to the anti-HRV activity of
oxysterols, first we used co-immunoprecipation assays to assess whe-
ther physical interaction between OSBP and VAP-A was disrupted in
25HC- or 27HC-treated MA104 cells.
Immunoprecipitation of VAP-A co-immunoprecipitated OSBP in
untreated cells and the reverse was demonstrated (Fig. 7A). Co-im-
muneprecipitation was specific since neither VAP-A nor OSBP was de-
tected in the immunoprecipitates obtained with an unrelevant antibody
used as a negative control. This result was consistent with previous
studies that showed a physical interaction between OSBP and VAP-A.
Interestingly, we found that the association of OSBP to VAP-A was
disrupted in the 25HC- or 27HC-treated cells. Control experiments
showed that the treatment did not down-regulate OSBP and VAP-A
protein levels (Fig. 7B). To explore whether OSBP and VAP-A play a
role in the antiviral activity exerted by 25HC or 27HC, we performed
target identification by siRNA sensitization (TISS) assay. This assay
allows to evaluate whether knockdown of OSBP or VAP-A results in
enhanced sensitivity to suboptimal concentrations of 25HC or 27HC.
Silencing of the expression of both proteins by specific siRNA im-
proved the antiviral efficacy of both 25HC and 27HC (Fig. 8A-B-D-E).
By contrast, no effect was observed when the cells were transfected
with a non-targeting siRNA. A slight but significant (pANOVA< 0.01)
block of HRV infectivity was measurable in the OSBP- and VAP-A-si-
lenced untreated cells (Fig. 8C-F). Taken together, these results prove
that OSBP and VAP-A are cellular determinants of the anti-HRV activity
elicited by 25HC and 27HC.
25HC and 27HC induce cholesterol accumulation in LEs
We next investigated by confocal immunomicroscopy whether
treatment of MA104 cells with 25HC or 27HC induces cholesterol ac-
cumulation in LEs. As a positive control, cells were treated with
U18666A, an amphipathic steroid 3-β-[2-(diethylamine)ethoxy] an-
drost-5-en-17-one that blocks the exit of free cholesterol from the LE
compartment. Cholesterol accumulation was visualized by filipin, a
fluorescent polyene antibiotic that binds to cholesterol but not to es-
terified sterols. As compared to the untreated cells, cholesterol accu-
mulation was observed in the LEs of the cells treated with the oxysterols
or U18666A, along with enlargement of the LE compartment (Fig. 9).
Like 25HC and 27HC, U18666A was found to be endowed with anti-
Fig. 4. Time of addition experiments. Panels A and B: time-of-addition experiments were performed by treating cells with 25HC(A) or 27HC(B) for 20 h or 4 h before
infection, for 1 h during infection or by adding the oxysterols immediately after infection. The infectivity titers of virus in the treated samples are expressed as a
percentage of the titer obtained in the absence of treatment. Error bars represent the standard error of the mean (SEM) of 3 independent experiments. Panel C shows
the effect of oxysterols on deposition of neosynthetized VP6 antigen as assessed by immunocytochemistry. Infected MA104 or Caco2 cell lines were fixed at 20 h post-
infection and stained with anti-VP6 antibody.
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HRV activity (Table 3; Fig. 10A, B, C, D, E), even when the cells were
infected with high MOIs (Fig. 10F), it was not endowed with antiviral
activity when added after HRV escape from LEs (Fig. 10G), when cells
were infected with an HRV suspension that skipped the endocytosis
steps (Fig. 10H), and it blocked the viruses penetrating inside the LEs
(Fig. 10I).
Discussion
Here we show that 25HC and 27HC sequester HRV Wa inside LEs
and that both are endowed with antiviral activity against the LEs-de-
pendent strains Wa, WI61, and DS-1, as well as against strains HRV248
and HRV408. Physiologic concentrations of 25HC and 27HC range from
Fig. 5. Evaluation of the step of HRV inhibited
by 25HC and 27HC. Panel A shows the effect of
oxysterols on binding to the MA104 cell surface.
On the y axis, the infectious titer of Wa bound to
cells is expressed as a % of the titer bound to
control untreated MA104 cells. Error bars re-
present the SEM of 3 independent experiments.
Panel B: HRV Wa entry kinetics on treated or
untreated MA104 cell monolayers. Virus was in-
oculated at 4 °C for 1 h, then temperature was
shifted to 37 °C. HRV-cell penetration was
stopped with EGTA in PBS at fixed time points.
On the y axis, the number of infected cells in the
treated or untreated samples is expressed as a
percentage of infected cells when no EGTA wash
was performed, which was taken as 100% entry.
Each point represents mean and SEM for tripli-
cates. Panel C: Effect of oxysterols on the in-
fectivity of EGTA-inactivated HRVWa transfected
with lipofectamine (black bars) or trypsin-acti-
vated HRV Wa (white bars). MA104 cells were
treated 20 h before inoculums. Panel D: Effect of
oxysterols when added after HRV escape from
LEs. Cells were infected for 45min, treated with
25mM of NH4Cl for 15min, then oxysterols were
added. In panels C-D, the percentage infection
was calculated by comparing treated and un-
treated wells. The results are means and SEM for
triplicates. ***pANOVA< 0.001.
Fig. 6. Intracellular localization of HRV VP6 antigen as assessed by immunofluorescence experiments. Infected MA104 were fixed at 8 h post-infection and stained
with anti-VP6 antibody (red signal) and anti-Rab7 antibody (green signal). The inserts in the right panels show the merged signals.
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1 to 25 µg/L for 25HC and from 25 to 250 µg/L for 27HC. The average
EC50s of 25HC against HRV strains are 0.15 µM as assessed on MA104
cells (corresponding to 60 µg/L), and 0.30 µM on Caco2 (corresponding
to 121 µg/L), being at supraphysiologic levels. Notably, average EC50s
of 27HC are 0.36 µM on MA104 cells (corresponding to 145 µg/L), and
0.49 µM on Caco2 (corresponding to 197 µg/L), being both in the
physiologic range of concentrations of this oxysterol. The intracellular
localization of HRV particles was assessed in immunofluorescence ex-
periments using a specific antibody directed to the intermediate capsid
protein VP6: since this antibody does not recognize the whole TLP
particle (VP6 is hidden beneath the external capsid), we can assume
that the HRV particles sequestered in the LEs of the oxysterol-treated
cells are DLPs. This suggests that oxysterols do not inhibit the dis-
assembly of the HRV external capsid (which would lead to permeabi-
lization of the LEs membrane), but rather they somehow modify the LE
milieu that halts the release of DLPs from LEs. Accumulation of cho-
lesterol within LE compartments has been shown to alter their function,
significantly impairing the infection of certain enveloped viruses that
enter the cell through endocytosis, such as Influenza A virus (IAV),
vescicular stomatitis virus (VSV), and dengue virus [38, 40, 41].
Oxysterols are implicated in endosomal cholesterol homeostasis
through their interaction with OSBP. Mammalian OSBP and OSBP-re-
lated proteins (ORPs) constitute a large eukaryotic gene family char-
acterized by a conserved C-terminal sterol-binding domain [42]. Their
primary function is to transfer cholesterol, ergosterol or oxysterols be-
tween target membranes and/or to transduce sterol-dependent signals
at these points of contact [43,44]. The OSBP possess N-terminal
pleckstrin homology (PH) domains that interact with phosphatidyli-
nositol (PI) phosphates [45,46] and two phenylalanines (FF) in an
acidic tract (FFAT) motif that bind the vesicle-associated membrane
protein–associated protein A (VAP-A) on the cytoplasmic surface of the
endoplasmic reticulum (ER; 47, 48). The complex VAP-A-OSBP med-
iates the transport of de novo synthesized cholesterol from the ER to
other intracellular organelles.
A recent study by Amini-Bavil-Olyaee and colleagues investigating
OSBP/VAP-A-mediated cholesterol shuttling as a cellular restriction
mechanism of innate immunity against enveloped viruses showed that
interferon-inducible transmembrane protein 3 (IFITM3) expression in-
duces substantial accumulation of cholesterol within LE compartments
in a VAP-A binding dependent manner [38]. IFITM3 was found to in-
teract with VAP-A and prevent its association with OSBP, so inducing a
marked accumulation of cholesterol in multivesicular bodies and LEs;
the latter event inhibited the fusion of intraluminal virion-containing
vesicles with endosomal membranes, thereby blocking virus release
into the cytosol of IAV and VSV.
To this end, Tanner and Lee commented on a novel and intriguing
antiviral mechanism they called “the greasy response” to viral infec-
tions: IFITM3 expressed at LE compartments interacts with VAP-A and
disrupts the ER resident complex between OSBP and VAP-A, leading to
cholesterol accumulation in LE, thus blocking virus entry [39]. An
eventual involvement of oxysterol (the highest affinity ligands of OSBP)
was never demonstrated.
In the present study, we demonstrate for the first time that oxy-
sterols can trigger this antiviral mechanism, and that this restriction
strategy can block the infectivity of a non-enveloped virus. Consistent
with previous data showing 25HC-induced translocation of OSBP from
the ER (where VAP-A is localized) to the Golgi [49], we show that
treatment with 25HC prevents the association of OSBP to VAP-A. More
interestingly, we report that even 27HC can abolish OSBP-VAP-A in-
teraction. Accordingly, both 25HC and 27HC appeared to induce a
substantial accumulation of cholesterol in the LE compartment.
In agreement with our initial hypothesis, the antiviral effect of
oxysterols was potentiated in the cells in which the expression of either
OSBP or VAP-A was silenced. The silencing of these proteins in the
untreated cells exerted a partial block of HRV infectivity, thus stressing
the involvement of these two proteins in HRV replication.
The present report also provides proof of concept that accumulation
of cholesterol within LEs is an effective anti-HRV mechanism. While
many studies have demonstrated the wide spectrum of antiviral activity
of U18666A against enveloped viruses [50–52], we provide the first
evidence of its antiviral potential against a non-enveloped virus. This
cationic amphiphile causes a significant block of HRV infectivity even
at high MOIs by inducing cholesterol accumulation on LEs and se-
questering HRV inside them. This finding opens the way to the search
for small anti-HRV molecules endowed with this molecular mechanism.
Cholesterol accumulation on the membrane of LEs leads to several
dramatic modifications of this intracellular compartment. Our results
show that cholesterol accumulation in the larger cholesterol-enriched
LEs in the 25HC-, 27HC-, and U18666A-treated cells leads to enlarge-
ment of LEs. Moreover, Sobo and colleagues showed that cholesterol
accumulation dramatically perturbs the back fusion of intraluminal
vesicles with the limiting membrane and intra-organellar trafficking
[53]. Inhibition of back fusion events is expected to severely interfere
with the sorting and trafficking of the proteins that cycle between in-
traluminal and limiting membranes, as was shown for the cation-de-
pendent mannose-6-phosphate receptor (CD-M6PR; 53). LE-dependent
HRVs are strictly dependent on the presence of the CD-M6PR on such
vesicles to become uncoated and exit the endosomal system [37]. These
cholesterol-induced perturbations of the LE compartment provide a
reasonable explanation for why cholesterol accumulation blocks HRV
particles inside these organelles.
In conclusion, both 25HC and 27HC appear to exert a remarkable
anti-HRV effect, based at least on the impairment of the OSBP/VAP-A
interplay and on abnormal cholesterol accumulation within LEs, the last
gate for the virus to enter the cytosol. Indeed, since these side chain
oxysterols have been shown to drive a number of biochemical reactions
within the cells [14], their direct action on LE structure and function
cannot be excluded.
This study discloses a totally novel mechanism of two oxysterols of
enzymatic origin suggesting that, besides 25HC, other members of this
Fig. 7. Panel A: effect of 25HC or 27HC treatment on the interaction of OSBP
and VAP-A, as assessed by coimmune precipitation experiments. A total amount
of 500 µg of proteins extracted from treated or untreated cells was pulled-down
with anti-VAP-A antibody (upper insert) or anti-OSBP antibody (lower insert)
overnight at 4 °C. A control (Ctrl(-)) pull-down was performed with or anti-VP6
antibody. The precipitated proteins were analyzed by immunoblotting. IP:
immune precipitation; WB: Western blot. Panel B: effect of 25HC or 27HC
treatment on the expression of OSBP and VAP-A. Actin blotting was used as
normalization.
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family could be actively involved in the innate immunity response
against viruses. To these end, our results demonstrate that lipid in-
volvement as host restriction strategy is an area of focus which, with the
recent advances in technology, holds great promise to discover novel
mechanisms and redox active lipid factors to develop innovative ap-
proaches for antiviral therapy.
Fig. 8. Effect of OSBP silencing (panels A, B, and
C) or VAP-A silencing (panels D, E, and F) by short
interfering RNA (siRNA) transfection on the anti-
viral activity of 25HC or 27HC. Cells were trans-
fected for 72h with 20nM of anti-OSBP siRNA,
anti-VAP-A siRNA or control non-interfering
siRNA. Cells were then treated for 20h with oxy-
sterols at sub-optimal concentrations and finally
infected with HRV Wa. Viral infections were de-
tected as described in the Material and Methods
section. The infectivity titers of virus in the treated
samples are expressed as a percentage of the titer
obtained in the absence of treatment. Error bars
represent the standard error of the mean (SEM) of
3 independent experiments.*pANOVA< 0.05;
**pANOVA< 0.01; ***pANOVA< 0.001.
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Fig. 9. Effect of 25HC or 27HC on intracellular localization of cholesterol. Positive control experiments were performed by treating cells with U18666A. Treated or
untreated MA104 were fixed at 20 h post-treatment and intracellular cholesterol was stained with filipin (blue signal)and late endosomes with anti-Rab7 antibody
(green signal). The inserts in the right panels show the merged signals.
Table 3
Antirotavirus activity of U18666A (MA104 cells).
Treatment HRV strain EC50a (µM) – 95% CIb EC90c (µM) – 95% CI CC50d (µM) –95% CI SIe
U18666A Wa 1.44 (1.17–1.78) 11.66 (7.63–17.83) 219.3 (180.6–266.4) 152.29
WI61 7.84 (7.08–8.68) 20.89 (16.72–26.09) 219.3 (180.6–266.4) 27.97
HRV408 2.14 (1.55–2.95) 12.04 (5.94–24.42) 219.3 (180.6–266.4) 102.47
HRV248 2.63 (1.74–3.80) 17.60 (7.05–43.94) 219.3 (180.6–266.4) 83.38
DS-1 5.84(4.76–7.16) 19.87 (12.43–31.74) 219.3 (180.6–266.4) 37.56
n.a. not assessable.
a EC50 half-maximal effective concentration.
b CI confidence interval.
c EC9090% effective concentration.
d CC50 half maximal cytotoxic concentration.
e SI selectivity index.
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Fig. 10. Assessment of the antiviral activity of
U18666A against HRV strains and assessment
of its mechanism of action. Cells were treated
for 20 h with increasing concentrations of
U18666A and then infected with HRV Wa (A),
WI61 (B), HRV 248 (C), DS-1 (D), and HRV
408 (E). Viral infections were detected as de-
scribed in the Material and Methods section.
The percentage infection was calculated by
comparing treated and untreated wells. The
results are means and SEM for
triplicates.***pANOVA< 0.001. Panel F: cells
were treated with 1.9 µM of U18666A for 20 h,
then infected with high multiplicities of infec-
tion (MOIs) of HRV Wa. The percentage in-
fection was calculated by comparing treated
and untreated wells. The results are means and
SEM for triplicates.**pANOVA< 0.01. Panel G:
effect of oxysterols when added after HRV es-
cape from LEs. Cells were infected for 45min,
treated with 25mM of NH4Cl for 15min, then
oxysterols were added. Panel H: effect of oxy-
sterols on the infectivity of EGTA-inactivated
HRV Wa transfected with lipofectamine (black
bars) or trypsin-activated HRV Wa (white
bars). MA104 cells were treated 20 h before
inoculums. * **pANOVA< 0.001 Panel I: in-
tracellular localization of HRV VP6 antigen as
assessed by immunofluorescence experiments.
Infected MA104 were fixed at 8 h post-infec-
tion and stained with anti-VP6 antibody (red
signal) and anti-Rab7 antibody (green signal).
The inserts in the right panels show the merged
signals.
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Materials and methods
Cell line and viruses
African green monkey kidney epithelial cells (MA104) and human
epithelial colorectal adenocarcinoma cells (Caco-2) were propagated in
Dulbecco's Modified Eagle Medium (DMEM; Sigma, St. Louis, MO, USA)
supplemented with 1% (v/v) Zell Shield (Minerva Biolabs, Berlin,
Germany) and heat inactivated, 10% (v/v) fetal bovine serum (Sigma).
Human rotavirus (HRV) strains Wa (ATCC® VR-2018), WI61 (ATCC®
VR-2551), HRV 408 (ATCC® VR-2273), HRV 248 (ATCC® VR-2274), DS-
1 (ATCC® VR-2550) were purchased from ATCC (American Type
Culture Collection, Rockville, MD, USA); virus was activated with 5 µg/
ml of porcine pancreatic trypsin type IX (Sigma) for 30min at 37 °C and
propagated in MA104 cells using DMEM containing 0.5 µg of trypsin
per ml as described previously [54]. Viral titers are expressed as focus-
forming unit (FFU) per ml.
Antibodies and reagents
25HC and 27HC (Sigma) were dissolved in sterile ethanol at con-
centrations ranging from 2.75mM to 3mM. U18666A was purchased
from Millipore (Darmstadt, Germany) and dissolved in sterile dimethyl
sulfoxide (DMSO) to a concentration of 5mM. Mouse monoclonal an-
tibody (MAb) directed to human rotavirus VP6 (2B4) was purchased
from Covalab (Villeurbanne, France). The rabbit polyclonal antibodies
directed to VAP-A (H-40: sc-98890) and Rab 7 (H-50: sc-10767) were
purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The
rabbit polyclonal antibody directed to OSBP (C2C3) was purchased
from GeneTex (Irvine, CA, USA). The rabbit polyclonal antibody to
OSBP-N-terminal (ab192990) was purchased from Abcam (Cambridge,
UK). The mouse monoclonal antibody directed to actin (MAB1501R)
was purchased from Millipore. The secondary antibody peroxidase-
conjugated AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (H+L)
was purchased from Jackson ImmunoResearch Laboratories Inc. (West
Grove, PA, USA). The secondary antibodies anti-mouse IgG horseradish
(HRP)-linked (NA931V) and anti-rabbit IgG HRP-linked (NA934V)
were purchased from GE Healthcare UK (Chalfont St Giles, UK). The
secondary antibodies goat anti-rabbit IgG-FITC (sc-2012) and goat anti-
mouse IgG-R (sc-2092) were purchased from Santa Cruz Biotechnology,
Inc.
Antiviral assays
The antiviral efficacy of the oxysterols was determined by focus
reduction assay on confluent MA104 or Caco2 cell monolayers plated in
96-well trays, as described elsewhere [21]. Cells were treated for 20 h
at 37 °C with 25HC, 27HC or U18666A at concentrations ranging from
0.07 to 16.7 µM (corresponding to 28.2 and 6724 µg/L for both oxy-
sterols, and 29.7 and 7082 µg/L for U18666A). Control samples (100%
of infectivity) were prepared by treating cells with culture medium
supplemented with equal volumes of ethanol or DMSO, corresponding
to 0.6% (v/v) to 0.0014% (v/v) in cell media. Cells were then washed
with medium and infected with HRV at a multiplicity of infection (MOI)
of 0.02 FFU/cell for 1 h, unless otherwise stated. Alternatively, MA104
cells were treated for 20 h with 25HC, 27HC, or U18666A at respective
EC90 concentrations and then infected for 1 h with HRV Wa at MOIs 10,
3, and 1. Experiments with EGTA-inactivated HRV were performed by
treating trypsin activated HRV Wa for 15min with 1.5mM EGTA at
room temperature. Infection was then performed for 1 h at 37 °C in
presence of Lipofectamine (Invitrogen Carlsbad, CA). This technique
represents a useful strategy to skip viral penetration through en-
docytosis while delivering in cytoplasm HRV DLPs ready to start viral
RNA transcription [55]. After infection, cells were washed with
medium and incubated at 37 °C in a humidified incubator in 5% (vol/
vol) CO2–95% (vol/vol) air until fixed. For time-of-addition assays,
serial dilutions of oxysterols were added on cells alternatively 20 h or
4 h before infection or during infection or post-infection. Alternatively,
cells were infected with trypsin-activated HRV Wa for 45min at 37 °C,
then medium supplemented with 25mM NH4Cl was added. This tech-
nique inhibits endosome acidification thereby sequestering HRV parti-
cles that are still inside the endosomes, while permitting the replication
of those that already escaped from LEs [56]. After 15min of incubation
at 37 °C, oxysterols in presence of 25mM NH4Cl were added. After each
one of these treatment/infection protocols, cells were incubated for
16 h, then fixed with cold acetone-methanol (50:50), and viral titers
were determined by indirect immunostaining. Blockade of viral in-
fectivity is expressed as mean % ± standard error of the mean (SEM).
Cell viability assay
Cells were seeded at a density of 5×103/well in 96-well plates and
treated the next day with oxysterols 25HC, 27HC, or U18666A at
concentrations ranging from 0.07 to 150 µM (corresponding to 28.2 and
60400 µg/L for both oxysterols, and 29.7 and 63609 µg/L for U18666A)
to generate dose-response curves. Control samples (100% of viability)
were prepared by treating cells with culture medium supplemented
with equal volumes of ethanol, corresponding to 0.6% (v/v) to 0.0025%
(v/v) in cell media. After 24 h of incubation, cell viability was de-
termined using a CellTiter 96 Proliferation Assay Kit (Promega,
Madison, WI, USA) and following the manufacturer's instructions.
Absorbances were measured using a Microplate Reader (Model 680,
Bio-Rad Laboratories, Hercules, CA, USA) at 490 nm. Viability of oxy-
sterol-treated cells is expressed as a percentage relative to cells in-
cubated with culture medium supplemented with equal volumes of
ethanol.
Rotavirus-cell binding assay
Rotavirus-cell binding assays were performed as described pre-
viously [54]. Confluent MA104 cell monolayers in 24-well trays were
treated with 25HC or 27HC at 1.8 µM or 5.6 µM. After 20 h, cells were
washed with fresh medium and cooled on ice. Trypsin-activated virus,
which had been cooled to 4 °C, was allowed to attach to cells for 1 h
(MOI=3 FFU/cell) at 4 °C. After a washing with cold DMEM, the cells
were subjected to two rounds of freeze-thawing and then incubated at
37 °C for 30min with 10 µg/ml porcine trypsin to release bound virus.
The lysates were clarified by low speed centrifugation for 10min. Cell-
bound virus titers were determined by indirect immunostaining as
above.
Rotavirus-cell entry assay
Confluent MA104 cell monolayers in 96-well plates were treated
with 25HC or 27HC at concentrations ranging from 0.07 to 16.7 µM.
After 20 h, cells were washed twice with DMEM and cooled on ice for
20min. Trypsin-activated virus, which had been cooled to 4 °C, was
adsorbed to cells on ice for 1 h at 4 °C (MOI=0.2 FFU/cell) to ensure
virus attachment but not entry. Unbound viruses were then washed,
warmed medium was added, and the plates were incubated at 37 °C in
humidified atmosphere to allow entry. At fixed timepoints (0, 15, 30,
45, 60, 75, 90min after virus-cell attachment), the medium in the wells
was aspirated, and viral particles still present on the cell surface were
detached by two quick washes with 3mM EGTA in PBS, followed by
incubation in warm medium. After reaching the last timepoint (90min),
the plates were placed into a CO2 incubator, and the infection was left
to proceed for an additional 16 h. The cells were then fixed and stained
by indirect immunostaining as described above. The amount of virus
that entered at each time point was compared to the amount of virus
that entered when no EGTA wash was performed, which was taken as
100% entry.
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Immunoblotting
Cells were lysed in denaturating conditions, unless otherwise stated.
Extracted proteins were denatured by boiling for 5min, then separated
by sodium dodecyl sulfate–12% polyacrylamide gel electrophoresis
(SDS-12% PAGE) and transferred to a polyvinylidene difluoride (PVDF)
membrane. Membranes were blocked overnight at 4 °C with PBS, 0.1%
Tween 20, and milk powder 10%. Membranes were then incubated
with primary antibodies for 1 h at 37 °C, washed 4 times with PBS, 0.1%
Tween 20, and 15% milk powder, then incubated for 1 h at 37 °C with
secondary antibodies coupled with HRP and washed extensively prior
to developing by the enhanced chemiluminescence method. The band
density was compared using ImageJ software, and the intensity of the
actin bands was used to normalize values. Where possible, the results
are expressed as a percentage, by comparing treated cells with cells
incubated with culture medium alone.
Immunofluorescence experiments
Subconfluent MA104 cell monolayers plated on coverslips in 24-
well plates were treated with 25HC, 27HC or U18666A at 1.8 µM. After
20 h, cells were infected with trypsin-activated rotavirus Wa (MOI = 10
FFU/cell) for 8 h at 37 °C. Cells were washed twice with PBS and then
fixed in cold acetone-methanol (50:50). Cells were blocked with 1%
BSA for 30min and then incubated with primary antibodies diluted in
blocking buffer for 1 h followed by three washes in PBS with 0.05%
Tween 20 and incubation with secondary antibodies diluted in blocking
buffer for 1 h. After washing three times with PBS, coverslips were
mounted and analyzed on a confocal fluorescence microscope (LSM510,
Carl Zeiss, Jena, Germany).
Co-immunoprecipitation experiments
MA104 cells were treated with 5.6 µM of 25HC or 27HC for 2 h at
37 °C and then lysed in non-denaturating conditions (Tris HCl pH8
20mM, NaCl 137mM, NP40 1%, EDTA 2mM, and 1X protease in-
hibitor mixture). The extracted proteins (500 µg) were incubated with
0.5 µg of VAP-A antibody, rabbit polyclonal to OSBP-N-terminal or anti-
VP6 antibody overnight at 4 °C. Protein A-Sepharose (15 µl in PBS with
0.1% Triton X-100) was added for 1 h at 4 °C. Sepharose beads were
collected by centrifugation and washed four times with 1ml of PBS
containing 1% NP40. The samples were heated to 97 °C in SDS sample
buffer, separated by SDS-PAGE, and analyzed by immunoblotting.
siRNA transfection experiments
Caco2 cells (2× 104) were transfected with 20 nM of siRNA against
OSBP, VAP-A or with control non-interfering siRNAs. Each sample of
transfected or untransfected cells was seeded in different wells in a 24-
well tray and cultured for 72 h at 37 °C (5% CO2). Cells were treated
with suboptimal concentrations (EC50) of 25HC or 27HC for 20 h, and
then infected with HRV Wa (MOI 0.02 FFU/cell) as previously de-
scribed. After 16 h, cells were fixed and subjected to indirect im-
munostaining to assess blockade of virus infectivity.
Quantitative real-time reverse transcription (RT)-PCR
The levels of siRNA-mediated silencing of OSBP or VAP-A expres-
sion were assessed by quantitative real-time reverse transcription (RT)-
PCR. Briefly, extraction of total RNA from transfected or untransfected
Caco2 cells was performed 72 h after transfection using TRIzol Reagent
(Applied Biosystems, Monza, Italy). Concentration and purity of the
extracted RNA were assessed by spectrophotometry (A260/A280).
Later, 2 µg of RNA were reverse transcribed by using a High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-
PCR was performed with 30 ng of cDNA using TaqMan Gene Expression
Assay kits for OSBP and β-actin, TaqMan Fast Universal PCR Master
Mix, and 7500 Fast Real-Time PCR System (Applied Biosystems). For
each gene, threshold cycles (Ct) were determined and results were
normalized using β-actin. Relative quantification was performed using
a previously published mathematical method [57].
Statistical analysis
Where possible, half-maximal antiviral effective concentration
(EC50) values were calculated by regression analysis using the dose-
response curves generated from the experimental data using GraphPad
PRISM 7 (GraphPad Software, San Diego, CA, USA). The 50% cytotoxic
concentration (CC50) was determined using logarithmic viability
curves. Where possible, a selectivity index (SI) was calculated by di-
viding the CC50 by the EC50 value. EC50 values were compared using the
sum-of-squares F test. One-way ANOVA, followed by Bonferroni test,
was used to assess the statistical significance of the differences between
treated and untreated samples, where appropriate. Significance was set
at the 95% level.
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